

Modified Form 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	09/941,282
Filing Date	August 28, 2001
First Named Inventor	Chaturvedi, et al.
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	VPI/01-119





U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS


Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No


OTHER NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	A1	Paul Glue, M.D., Ph.D., "The Clinical Pharmacology of Ribavirin", Seminars in Liver Disease, Vol. 19, 17-24, Supplement 1, 1999.
	A2	Khakoo et al., "Ribavirin and Interferon Alfa-2b in Chronic Hepatitis C: Assessment of Possible Pharmacokinetic and Pharmacodynamic Interactions", Br. J. Clin Pharmacol, 46: 563-570, 1998.
	A3	Brunet et al., "Pharmacokinetics and Pharmacodynamics of Mycophenolic Acid in Stable Renal Transplant Recipients Treated with Low Doses of Mycophenolate Mofetil", Transpl. Int. 13 [Suppl 1] S301-S305, 2000.
	A4	McHutchinson et al., "Combination Therapy With Interferon Plus Ribavirin for the Initial Treatment of Chronic Hepatitis C", Seminars in Liver Disease, 19: [Suppl. 1] 57-65, 1999

FEB 28 2002

TECH CENTER 1600/2900

[illegible]

Examiner Signature		Date Considered	7/02/02
-----------------------	---	--------------------	---------

Include copy of this form with next communication to applicant.